The company sources GMP-grade bone marrow from multiple suppliers, including Secretome, who harvest tissue from young, healthy consenting adult donors. These suppliers currently fulfill the company's requirements; however, the loss of any supplier could affect the production of laromestrocel. The company manufactures investigational product candidates in its own cGMP facility equipped with ISO 7 cleanrooms. Occasionally, excess manufacturing capacity is utilized to provide contract manufacturing and development services to third parties, although business development in this area remains limited. On February 21, 2024, the company entered into a five-year Supply Agreement with a third-party biotechnology company developing novel secretomes to manufacture, test, release, and supply a product containing cardiac stem cells for Phase 1 and Phase 2 clinical trials. The company received an initial start-up payment and bills the third party on a variable fee basis for testing and project management services. Activities under this agreement decreased substantially in 2025, with only limited contract testing ongoing and no significant future revenue expected from the agreement.
Longeveron Inc's Comment on Supply Chain
The company sources GMP-grade bone marrow from multiple suppliers, including Secretome, who harvest tissue from young, healthy consenting adult donors. These suppliers currently fulfill the company's requirements; however, the loss of any supplier could affect the production of laromestrocel. The company manufactures investigational product candidates in its own cGMP facility equipped with ISO 7 cleanrooms. Occasionally, excess manufacturing capacity is utilized to provide contract manufacturing and development services to third parties, although business development in this area remains limited. On February 21, 2024, the company entered into a five-year Supply Agreement with a third-party biotechnology company developing novel secretomes to manufacture, test, release, and supply a product containing cardiac stem cells for Phase 1 and Phase 2 clinical trials. The company received an initial start-up payment and bills the third party on a variable fee basis for testing and project management services. Activities under this agreement decreased substantially in 2025, with only limited contract testing ongoing and no significant future revenue expected from the agreement.
Sources:
Longeveron Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Longeveron Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
